Table 8.

Change in Visual Acuity from Baseline to 56-Week Visit^*

	Sham+ Focal/Grid/PRP Laser	Ranibizumab+ Focal/Grid/PRP Laser	Triamcinolone+ Focal/Grid/PRP Laser
	N = 111	N = 95	N = 93
Change in visual acuity (letter score)
Mean±standard deviation	−6±17	−4±21	−5±16
Median (25th, 75th percentile)	−3 (−11, +4)	+1 (−12, +8)	−3 (−12, +3)
Difference in mean change from sham+focal/grid/PRP laser (95% CI) [P Value]†		+1.9 (−3.7, +7.5) [P = 0.44]	+1.2 (−4.4, +6.8) [P = 0.63]
Distribution of change, no. (%)
≥15 letter improvement	6 (5%)	12 (13%)	7 (8%)
14–10 letter improvement	9 (8%)	10 (11%)	5 (5%)
9–5 letter improvement	9 (8%)	12 (13%)	8 (9%)
Same ±4 letters	39 (35%)	27 (28%)	31 (33%)
5–9 letters worse	16 (14%)	8 (8%)	14 (15%)
10–14 letters worse	8 (7%)	8 (8%)	8 (9%)
≥15 letters worse	24 (22%)	18 (19%)	20 (22%)
Difference in proportion with ≥10 letter improvement from sham+ focal/grid/PRP laser (95% CI)‡		+8% (−4%, +20%)	+0.2% (−10%, +10%)
Relative risk (95% CI)     [P Value]† for comparison with sham+focal/grid/PRP laser	1.0	2.00 (1.04, 3.87) [P = 0.02]	1.22 (0.57, 2.63) [P = 0.55]
Difference in proportion with ≥10 letter worsening from sham+focal/grid/PRP laser (95% CI)‡		−1% (−15%, +13%)	+2% (−13%, +16%)
Relative risk (95% CI)     [P Value]† for comparison with sham+focal/grid/PRP laser	1.0	0.95 (0.58, 1.55) [P = 0.82]	1.04 (0.64, 1.69) [P = 0.85]

^*Visits occurring between 315 and 468 days (between 45 and 67 weeks) from randomization were included as 56-week visits. When more than 1 visit occurred in this window, data from the visit closest to the 56-week target date were used.

^† Adjusted for baseline visual acuity, number of planned panretinal photocoagulation (PRP) sittings, and correlation between 2 study eyes. Confidence intervals (CI) are adjusted for multiple comparisons.

^‡Adjusted for correlation between 2 study eyes. Confidence intervals are adjusted for multiple comparisons.